Small molecule-based Lifespan extension therapy: 17β-E2 (An estrogen derivative) increases life span via up regulation of its target gene BubR1, 11/April/2015, 22.03

Lifespan extension therapy: E2F1 decreases aging-related decline in muscle function and enhances the longevity of mammals via down regulation of myostatin, 11/April/2015, 16.36
April 11, 2015
MiRNA-based therapy for Lipid metabolism disorders: TGF-β1 inhibits the expression of IDH1 and lipid accumulation via up regulation of its target gene, 11/April/2015, 22.12
April 11, 2015
Show all

A recent study from the Department of Genetics, Paul F. Glenn Laboratories for the Biological Mechanisms of Aging Harvard Medical School, Boston,USA; and Department of Pharmacology, School of Medicine, The University of New South Wales, Australia shows that Sirtuin-2 induces the checkpoint kinase BubR1 to increase lifespan. This study was published in the 1 July  2014 issue of the journal  “EMBO” by Prof Sinclair, North BJ, and others.

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Small moleculebased Lifespan extension therapy: 17β-E2(An estrogen derivative) increases life span via up regulation of its target gene BubR1. Thus, pharmacological formulations encompassing 17β-E2 or its analogues” may be used to extend the lifespan of an individual. 

Idea Proposed/Formulated byDr L Boominathan Ph.D.

Web: http://genomediscovery.org

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Undisclosed information: How 17β-E2 increases the expression of BubR1

To citeBoominathan, Small molecule-based Lifespan extension therapy: 17β-E2(An estrogen derivative) increases life span via up regulation of its target gene BubR1, 11/April/2015, 22.04,  Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite drop us a line at info@genomediscovery.org

* Research cooperation

Comments are closed.